Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Cancer Prevention Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial

NCT07443943
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Localized Breast Carcinoma
Interventions
Starch, Potato
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jun 26, 2026, 5:38 PM EDT
Recruiting Phase 2 Interventional

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

NCT06113016
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Exercise Intervention, Fisetin, Physical Performance Testing, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Alhambra, California • Beverly Hills, California • Burbank, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Phase 3 Interventional

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

NCT00049452
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Stamford, Connecticut • Paramus, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of Exercise on Sex Hormones in Postmenopausal Women

NCT00668174
View directory record Official record
Conditions
Breast Cancer Prevention
Interventions
Exercise
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Phase 3 Interventional

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

NCT00022087
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
calcium salts, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
40 Years and older · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
107
States / cities
Arroyo Grande, California • La Jolla, California • Mountain View, California + 80 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Olive Oil for High Risk Breast Cancer Prevention in Women

NCT02068092
View directory record Official record
Conditions
Breast Cancer
Interventions
Hydroxytyrosol
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jun 26, 2026, 5:38 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention

NCT05524480
View directory record Official record
Conditions
Cancer Prevention
Interventions
Salud en Mis Manos - Dissemination and Implementation Assistance, Salud en Mis Manos- Usual Implementation Practice
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jun 26, 2026, 5:38 PM EDT
Not yet recruiting Phase 2 Interventional

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

NCT07499999
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions
Exemestane, Tamoxifen
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SCOPE-Chinese Women Study

NCT04326660
View directory record Official record
Conditions
Cancer, Breast, Obesity, Abdominal
Interventions
SCOPE-Chinese Women
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jun 26, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)

NCT06322888
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female
Interventions
Exercise Training Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients

NCT04256512
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Medical Device Usage and Evaluation, Questionnaire Administration
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jun 26, 2026, 5:38 PM EDT
Completed No phase listed Observational

Cancer Screening and Prevention Program for High Risk Women

NCT00849199
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
1,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention

NCT00723398
View directory record Official record
Conditions
Breast Cancer
Interventions
Lovaza 4gm oral, Raloxifene 60 Mg Oral Tablet, Raloxifene 30 Mg Oral Tablet, Lovaza 4gm & Raloxifene 30mg
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Jun 26, 2026, 5:38 PM EDT
Completed No phase listed Observational

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

NCT00040222
View directory record Official record
Conditions
Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Jun 26, 2026, 5:38 PM EDT
Active, not recruiting Not applicable Interventional

Increasing Screening for Cancer Using EHR-Nudges Replication

NCT06995703
View directory record Official record
Conditions
Breast Cancer
Interventions
Pre-Visit Patient Text Message, Post-Visit Patient Text Messages, Smart Data Element (SDE)
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
8,490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 26, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ

NCT01060345
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Polyphenon E
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

NCT01479244
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection
Biological
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
81
States / cities
Bessemer, Alabama • Mobile, Alabama • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jun 26, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Prevention of Osteoporosis in Breast Cancer Survivors

NCT00567606
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Strength/Weight Training & Drug/Supplement, Drug/Supplement only
Other · Combination Product
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Kearney, Nebraska • Lincoln, Nebraska • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Jun 26, 2026, 5:38 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Validation of a Tear-based Screening Assay for Breast Cancer

NCT04928014
View directory record Official record
Conditions
Healthy, Breast Cancer, Breast Cancer Female, Health Care Utilization, Health Knowledge, Attitudes, Practice, Health Personnel Attitude, Health Care Acceptability
Interventions
Schirmer Strip
Other
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jun 26, 2026, 5:38 PM EDT
Completed No phase listed Observational

The Effects of Radiation in Reconstructed Breasts

NCT01292772
View directory record Official record
Conditions
Breast Cancer
Interventions
contract-enhanced MRI, Unilateral Adjuvant Radiation Therapy
Procedure · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Jun 26, 2026, 5:38 PM EDT
Not listed Not applicable Interventional Results available

Scalp Cooling to Prevent Chemo-induced Hair Loss

NCT01986140
View directory record Official record
Conditions
Breast Cancer, Alopecia
Interventions
PAXMAN Orbis Scalp Cooler, Control No treatment
Device · Other
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older · Female only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
7
States / cities
Morristown, New Jersey • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Jun 26, 2026, 5:38 PM EDT